Scientists studying the brains of people in their 80s, 100s, and those with dementia have uncovered a pivotal moment in Alzheimer's disease—a cellular shift that appears to determine whether the disease leads to cognitive decline or not. Researchers from VIB, KU Leuven, the UK-DRI, and Muna Therapeutics identified this critical transition by examining brain tissue from older adults with and without cognitive decline, including cognitively healthy centenarians, and their findings, published in Nature Medicine, reveal how the brain's immune cells may hold the key to understanding why some people develop dementia while others resist it.
Alzheimer's disease affects more than 55 million people worldwide and is defined by the buildup of amyloid-β plaques and tau tangles in the brain. Yet here lies a paradox that has puzzled scientists for years: some individuals accumulate these hallmarks yet remain cognitively sharp, while others decline. The answer, researchers increasingly believe, lies not in the plaques and tangles themselves but in how the brain's cells respond to them.
The research team used cutting-edge spatial transcriptomics and single-cell sequencing to map the disease at unprecedented detail, identifying six distinct tissue domains representing different stages of Alzheimer's progression. What emerged was a striking turning point: a transition between domains dominated by amyloid-β plaques and those linked to tau pathology and neurodegeneration. This transition was accompanied by a dramatic shift in microglia—the brain's resident immune cells that act as its first line of defense.
Early in the disease process, microglia adopted an inflammatory state associated with amyloid plaques. But as the disease progressed, these cells switched to a distinct antigen-presenting state that coincided with the emergence of tau pathology. This cellular switch may represent the crucial moment that determines whether Alzheimer's pathology spirals toward dementia or remains held in check.
What makes this discovery even more illuminating is that resilience to Alzheimer's can take different biological routes. Octogenarians who had accumulated amyloid plaques but remained cognitively healthy showed an early microglial response to those plaques—but crucially, they did not transition into the later immune state associated with disease progression. They essentially stopped at an earlier checkpoint.
Centenarians displayed an entirely different pattern. Although their brains activated the later microglial program, this response occurred largely independent of tau accumulation. In other words, a cellular state linked to neurodegeneration in some individuals appeared to be uncoupled from harmful effects in others. These findings suggest that resilience is not simply the absence of pathology but rather the presence of distinct protective mechanisms.
Prof. Bart De Strooper, co-senior author of the study and a leading researcher at the VIB-KU Leuven Center for Neuroscience, describes the research as "an exciting journey," one that "provides insight into one type of resilience mechanism in the progression of AD to dementia." His colleague Prof. Mark Fiers adds that understanding how the brain resists disease "will provide new avenues towards therapies to prevent neurodegeneration and dementia."
The implications are profound. By identifying the specific microglial states and transitions that distinguish resilience from decline, researchers have pinpointed potential targets for future treatments—not necessarily to eliminate plaques and tangles, but to help the brain's immune cells respond in ways that protect cognition.